BioCentury | Jun 25, 2009
Strategy

Science for export

...2001 Dresden, Germany $10.9M Kinaxo Biotechnologies GmbH Cellular target profiling services 2005 Martinsried, Germany $764K RNAx GmbH...
BioCentury | Sep 26, 2005
Company News

Nucleis SA, RNAx sales and marketing update

...Nucleis and RNAx will co-market shRNA target validation technology. The deal combines Nucleis' Speedy Mouse transgenic...
...Speedy Mouse transgenic animal generation technology with RNAx's shRNA constructs. Nucleis SA , Lyon, France RNAx GmbH...
BioCentury | Apr 5, 2004
Company News

RNAx, Funakoshi Co. Ltd. sales and marketing update

...Funakoshi will exclusively market in Japan RNAx's services based on its RNAi technology for use in...
...technology for use in validating siRNA oligos and genetic targets for experimental and therapeutic use. RNAx GmbH...
BioCentury | Feb 2, 2004
Company News

Alnylam, RNAx deal

...Alnylam business unit Ribopharma AG (Kulmbach, Germany) licensed to RNAx non-exclusive rights to IP covering the...
...use of short double-stranded RNAs to elicit RNAi for use in RNAx's research services business. RNAx...
...initial and annual license fees plus royalties to Ribopharma. Alnylam Pharmaceuticals Inc. , Cambridge, Mass. RNAx GmbH...
BioCentury | Mar 31, 2003
Company News

metaGen GmbH, RNAx deal

...Functional genomics company RNAx granted metaGen access to its RNA interference (RNAi) validation technology. metaGen will...
...use the technology to validate cancer gene targets, and retains the rights to all results. RNAx...
...scientists from the Max Planck Institute for Infection Biology . metaGen GmbH , Berlin, Germany RNAx GmbH...
BioCentury | Mar 25, 2003
Company News

metaGen, RNAx target deal

...Functional genomics company RNAx (Berlin, Germany) granted metaGen (Berlin, Germany) access to its RNA interference (RNAi...
...use the technology to validate cancer gene targets, and retains the rights to all results. RNAx...
Items per page:
1 - 6 of 6
BioCentury | Jun 25, 2009
Strategy

Science for export

...2001 Dresden, Germany $10.9M Kinaxo Biotechnologies GmbH Cellular target profiling services 2005 Martinsried, Germany $764K RNAx GmbH...
BioCentury | Sep 26, 2005
Company News

Nucleis SA, RNAx sales and marketing update

...Nucleis and RNAx will co-market shRNA target validation technology. The deal combines Nucleis' Speedy Mouse transgenic...
...Speedy Mouse transgenic animal generation technology with RNAx's shRNA constructs. Nucleis SA , Lyon, France RNAx GmbH...
BioCentury | Apr 5, 2004
Company News

RNAx, Funakoshi Co. Ltd. sales and marketing update

...Funakoshi will exclusively market in Japan RNAx's services based on its RNAi technology for use in...
...technology for use in validating siRNA oligos and genetic targets for experimental and therapeutic use. RNAx GmbH...
BioCentury | Feb 2, 2004
Company News

Alnylam, RNAx deal

...Alnylam business unit Ribopharma AG (Kulmbach, Germany) licensed to RNAx non-exclusive rights to IP covering the...
...use of short double-stranded RNAs to elicit RNAi for use in RNAx's research services business. RNAx...
...initial and annual license fees plus royalties to Ribopharma. Alnylam Pharmaceuticals Inc. , Cambridge, Mass. RNAx GmbH...
BioCentury | Mar 31, 2003
Company News

metaGen GmbH, RNAx deal

...Functional genomics company RNAx granted metaGen access to its RNA interference (RNAi) validation technology. metaGen will...
...use the technology to validate cancer gene targets, and retains the rights to all results. RNAx...
...scientists from the Max Planck Institute for Infection Biology . metaGen GmbH , Berlin, Germany RNAx GmbH...
BioCentury | Mar 25, 2003
Company News

metaGen, RNAx target deal

...Functional genomics company RNAx (Berlin, Germany) granted metaGen (Berlin, Germany) access to its RNA interference (RNAi...
...use the technology to validate cancer gene targets, and retains the rights to all results. RNAx...
Items per page:
1 - 6 of 6